8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Apr 16, 2026·SEC
Material company update
Feb 25, 2026·SEC
MiMedx Group, Inc.(MDXG)Earnings, Financials & Key Ratios
MDXG•NASDAQ
$3.66
$544M mkt cap·11.4× P/E·Price updated May 6, 2026
AboutMiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.Show more
- Revenue$419M+20.0%
- EBITDA$79M+21.4%
- Net Income$49M+14.5%
- EPS (Diluted)0.32+14.3%
- Gross Margin82.56%-0.3%
- EBITDA Margin18.82%+1.1%
- Operating Margin15.26%-9.6%
- Net Margin11.6%-4.6%
- ROE21.61%-14.5%
- ROIC42.31%+6.5%
- Debt/Equity0.09-31.7%
- Interest Coverage38.16-35.3%
MDXG Key Insights
MiMedx Group, Inc. (MDXG) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Excellent 3Y average ROE of 36.3%
- ✓FCF machine: 17.4% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 11.0%
- ✓Efficient asset utilization: 1.2x turnover
✗Weaknesses
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MDXG Price & Volume
MiMedx Group, Inc. (MDXG) stock price & volume — 10-year historical chart
Loading chart...
MDXG Growth Metrics
MiMedx Group, Inc. (MDXG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.38%
5 Years11.02%
3 Years16.05%
TTM10.51%
Profit CAGR
10 Years5.13%
5 Years-
3 Years-
TTM-23.61%
EPS CAGR
10 Years2.1%
5 Years-
3 Years-
TTM-25.51%
Return on Capital
10 Years3.33%
5 Years12.36%
3 Years25.83%
Last Year25.72%
MDXG Recent Earnings
MiMedx Group, Inc. (MDXG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Apr 29, 2026EPS
$0.05
Est $0.07
+28.6%
Revenue
$59M
Est $66M
-10.3%
Q1 2026
Feb 25, 2026EPS
$0.14
Est $0.09
+55.6%
Revenue
$118M
Est $107M
+10.6%
Q4 2025
Oct 29, 2025EPS
$0.15
Est $0.07
+114.3%
Revenue
$114M
Est $107M
+6.4%
Q3 2025
Jul 30, 2025EPS
$0.10
Est $0.06
+66.7%
Revenue
$99M
Est $93M
+5.7%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.05vs $0.07+28.6% | $59Mvs $66M-10.3% |
| Q1 2026 | Feb 25, 2026 | $0.14vs $0.09+55.6% | $118Mvs $107M+10.6% |
| Q4 2025 | Oct 29, 2025 | $0.15vs $0.07+114.3% | $114Mvs $107M+6.4% |
| Q3 2025 | Jul 30, 2025 | $0.10vs $0.06+66.7% | $99Mvs $93M+5.7% |
Based on last 12 quarters of dataView full earnings history →
MDXG Peer Comparison
MiMedx Group, Inc. (MDXG) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NAUT | 373.61M | 2.94 | -6.26 | -35.04% | 0.19 | |||
 OSUR | 215.9M | 3.00 | -3.19 | -38.1% | -61.93% | -19.46% | 0.04 | |
 TELA | 39.94M | 0.99 | -0.74 | 18.56% | -50.61% | -272.13% | 1.51 | |
 APOG | 783.61M | 36.43 | 14.46 | 3.21% | 3.85% | 10.79% | 0.56 | |
 MASI | 9.35B | 178.49 | -63.74 | -27.1% | 4.9% | 9.08% | 0.78 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ITGR | 2.97B | 86.29 | 29.86 | 7.57% | 7.67% | 8.23% | 0.80 | |
 ATRC | 1.42B | 28.01 | -116.71 | 14.88% | -0.83% | -0.95% | 0.18 |
Compare MDXG vs Peers
MiMedx Group, Inc. (MDXG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDXG Income Statement
MiMedx Group, Inc. (MDXG) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 321.14M | 359.11M | 299.25M | 248.23M | 242.02M | 267.84M | 321.48M | 348.88M | 418.63M | 389.42M |
| Revenue Growth % | 31.07% | 11.82% | -16.67% | -17.05% | -2.5% | 10.67% | 20.03% | 8.52% | 19.99% | 10.51% |
| Cost of Goods Sold | 35.22M | 36.39M | 43.08M | 39.33M | 39.63M | 48.32M | 54.63M | 60.07M | 73.01M | 73.82M |
| COGS % of Revenue | 10.97% | 10.13% | 14.4% | 15.84% | 16.37% | 18.04% | 16.99% | 17.22% | 17.44% | - |
| Gross Profit | 285.92M▲ 0% | 322.73M▲ 12.9% | 256.17M▼ 20.6% | 208.9M▼ 18.5% | 202.39M▼ 3.1% | 219.53M▲ 8.5% | 266.84M▲ 21.6% | 288.81M▲ 8.2% | 345.62M▲ 19.7% | 315.59M▲ 0% |
| Gross Margin % | 89.03% | 89.87% | 85.6% | 84.16% | 83.63% | 81.96% | 83.01% | 82.78% | 82.56% | 81.04% |
| Gross Profit Growth % | 34.48% | 12.87% | -20.62% | -18.45% | -3.12% | 8.47% | 21.55% | 8.23% | 19.67% | - |
| Operating Expenses | 239.7M | 326.65M | 277.33M | 254.3M | 209.44M | 234.25M | 229.73M | 229.94M | 281.29M | 275.88M |
| OpEx % of Revenue | 74.64% | 90.96% | 92.67% | 102.44% | 86.54% | 87.46% | 71.46% | 65.91% | 67.19% | - |
| Selling, General & Admin | 219.53M | 295.25M | 264.71M | 240.49M | 194.85M | 220.85M | 216.3M | 216.39M | 266.19M | 259.46M |
| SG&A % of Revenue | 68.36% | 82.22% | 88.46% | 96.88% | 80.51% | 82.46% | 67.28% | 62.02% | 63.59% | - |
| Research & Development | 17.9M | 15.77M | 11.14M | 11.71M | 9.93M | 12.7M | 12.66M | 12.34M | 15.1M | 15.91M |
| R&D % of Revenue | 5.57% | 4.39% | 3.72% | 4.72% | 4.1% | 4.74% | 3.94% | 3.54% | 3.61% | - |
| Other Operating Expenses | 2.27M | 15.63M | 1.49M | 2.1M | 4.66M | 701K | 762K | 1.21M | 0 | 513K |
| Operating Income | 46.22M▲ 0% | -3.92M▼ 108.5% | -21.16M▼ 439.2% | -45.4M▼ 114.5% | -7.05M▲ 84.5% | -14.73M▼ 108.9% | 37.12M▲ 352.0% | 58.87M▲ 58.6% | 63.89M▲ 8.5% | 39.59M▲ 0% |
| Operating Margin % | 14.39% | -1.09% | -7.07% | -18.29% | -2.91% | -5.5% | 11.55% | 16.87% | 15.26% | 10.17% |
| Operating Income Growth % | 5128.85% | -108.49% | -439.25% | -114.55% | 84.47% | -108.86% | 352.03% | 58.6% | 8.53% | - |
| EBITDA | 51.99M | 2.99M | -13.57M | -38.54M | -1.87M | -10.68M | 40.54M | 64.91M | 78.77M | 52.86M |
| EBITDA Margin % | 16.19% | 0.83% | -4.54% | -15.53% | -0.77% | -3.99% | 12.61% | 18.6% | 18.82% | 13.57% |
| EBITDA Growth % | 718.19% | -94.24% | -553.71% | -183.93% | 95.15% | -471.79% | 479.58% | 60.09% | 21.36% | -15.31% |
| D&A (Non-Cash Add-back) | 5.76M | 6.92M | 7.58M | 6.86M | 5.18M | 4.05M | 3.43M | 6.04M | 14.88M | 13.27M |
| EBIT | 46.81M | 10.68M | -20.71M | -44.37M | -7.07M | -14.73M | 37.12M | 59.31M | 68.05M | 42.15M |
| Net Interest Income | -87K | 527K | -4.71M | -7.94M | -4.98M | -5.02M | -6.46M | -1.01M | 2.93M | 1.74M |
| Interest Income | 0 | 527K | 0 | 0 | 0 | 0 | 0 | 0 | 4.72M | 3.41M |
| Interest Expense | 87K | 0 | 4.71M | 7.94M | 4.98M | 5.02M | 6.46M | 1.01M | 1.78M | 1.67M |
| Other Income/Expense | -1.14M | 527K | -4.42M | -16.14M | -5M | -5.02M | -6.48M | -1.57M | 2.38M | 2.73M |
| Pretax Income | 45.09M▲ 0% | -3.4M▼ 107.5% | -25.59M▼ 653.2% | -61.54M▼ 140.5% | -12.05M▲ 80.4% | -19.75M▼ 63.8% | 30.63M▲ 255.1% | 57.29M▲ 87.0% | 66.26M▲ 15.7% | 42.32M▲ 0% |
| Pretax Margin % | 14.04% | -0.95% | -8.55% | -24.79% | -4.98% | -7.37% | 9.53% | 16.42% | 15.83% | 10.87% |
| Income Tax | -19.64M | 26.58M | -5K | -12.26M | 247K | 206K | -36.81M | 15.3M | 17.68M | 11.62M |
| Effective Tax Rate % | -43.56% | -782.51% | 0.02% | 19.92% | -2.05% | -1.04% | -120.15% | 26.7% | 26.69% | 27.47% |
| Net Income | 64.73M▲ 0% | -29.98M▼ 146.3% | -25.58M▲ 14.7% | -49.28M▼ 92.7% | -12.3M▲ 75.0% | -30.2M▼ 145.5% | 67.44M▲ 323.3% | 42.42M▼ 37.1% | 48.58M▲ 14.5% | 30.7M▲ 0% |
| Net Margin % | 20.16% | -8.35% | -8.55% | -19.85% | -5.08% | -11.27% | 20.98% | 12.16% | 11.6% | 7.88% |
| Net Income Growth % | 440.56% | -146.32% | 14.67% | -92.67% | 75.04% | -145.48% | 323.33% | -37.1% | 14.52% | -23.61% |
| Net Income (Continuing) | 64.73M | -29.98M | -25.58M | -49.28M | -12.3M | -19.95M | 67.44M | 42M | 48.58M | 30.7M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -10.24M | 0 | 421K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.56▲ 0% | -0.28▼ 150.0% | -0.24▲ 14.3% | -0.46▼ 91.7% | -0.09▲ 79.7% | -0.27▼ 189.7% | 0.38▲ 240.7% | 0.28▼ 26.3% | 0.32▲ 14.3% | 0.21▲ 0% |
| EPS Growth % | - | -150% | 14.29% | -91.67% | 79.74% | -189.7% | 240.74% | -26.32% | 14.29% | -25.51% |
| EPS (Basic) | 0.61 | -0.28 | -0.24 | -0.46 | -0.09 | -0.27 | 0.48 | 0.29 | 0.33 | - |
| Diluted Shares Outstanding | 116.11M | 105.6M | 106.95M | 108.26M | 110.35M | 112.91M | 145.96M | 149.05M | 149.72M | 148.45M |
| Basic Shares Outstanding | 106.12M | 105.6M | 106.95M | 108.26M | 110.35M | 112.91M | 116.5M | 146.98M | 147.79M | 148.45M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MDXG Balance Sheet
MiMedx Group, Inc. (MDXG) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 48.75M | 74.05M | 123.25M | 160.62M | 148.52M | 134.2M | 164.26M | 191.89M | 277.47M | 240.33M |
| Cash & Short-Term Investments | 27.48M | 45.12M | 69.07M | 95.81M | 87.08M | 65.95M | 82M | 104.42M | 166.12M | 159.77M |
| Cash Only | 27.48M | 45.12M | 69.07M | 95.81M | 87.08M | 65.95M | 82M | 104.42M | 166.12M | 159.77M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 656K | 454K | 32.33M | 35.42M | 40.35M | 43.08M | 53.87M | 55.83M | 75.71M | 46.03M |
| Days Sales Outstanding | 0.75 | 0.46 | 39.43 | 52.09 | 60.86 | 58.71 | 61.16 | 58.41 | 66.01 | 63.07 |
| Inventory | 9.47M | 15.99M | 9.1M | 10.36M | 11.39M | 13.18M | 21.02M | 23.81M | 25.34M | 26.23M |
| Days Inventory Outstanding | 98.11 | 160.36 | 77.13 | 96.15 | 104.9 | 99.59 | 140.44 | 144.65 | 126.68 | 127.27 |
| Other Current Assets | 9.02M | 5.82M | 6.08M | 13.42M | 3.55M | 4.67M | 1.75M | 2.82M | 10.3M | 8.29M |
| Total Non-Current Assets | 72.51M | 48.8M | 43.92M | 41.41M | 39.41M | 37.23M | 74.79M | 72.03M | 65.18M | 68.35M |
| Property, Plant & Equipment | 14.09M | 17.42M | 15.72M | 15.06M | 13.86M | 11.26M | 9.11M | 11.55M | 4.71M | 4.76M |
| Fixed Asset Turnover | 22.79x | 20.61x | 19.03x | 16.48x | 17.46x | 23.80x | 35.30x | 30.21x | 88.82x | 52.77x |
| Goodwill | 19.98M | 19.98M | 19.98M | 19.98M | 19.98M | 19.44M | 19.44M | 19.44M | 19.44M | 19.44M |
| Intangible Assets | 10.03M | 9.61M | 7.78M | 6M | 5.38M | 5.85M | 5.26M | 11.63M | 14.16M | 13.14M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.87M | 1.79M | 443K | 375K | 186K | 683K | 205K | 1.11M | 7.27M | 18.14M |
| Total Assets | 121.25M▲ 0% | 122.84M▲ 1.3% | 167.17M▲ 36.1% | 202.03M▲ 20.9% | 187.93M▼ 7.0% | 171.43M▼ 8.8% | 239.05M▲ 39.4% | 263.92M▲ 10.4% | 342.65M▲ 29.8% | 308.68M▲ 0% |
| Asset Turnover | 2.65x | 2.92x | 1.79x | 1.23x | 1.29x | 1.56x | 1.34x | 1.32x | 1.22x | 1.23x |
| Asset Growth % | -37.26% | 1.31% | 36.08% | 20.86% | -6.98% | -8.78% | 39.44% | 10.4% | 29.83% | 101.24% |
| Total Current Liabilities | 45.81M | 71.55M | 67.32M | 59.16M | 42.36M | 43.56M | 46.01M | 45.59M | 64.27M | 44.55M |
| Accounts Payable | 8.45M | 14.86M | 8.71M | 8.77M | 7.38M | 8.45M | 9.05M | 7.41M | 14.53M | 11.46M |
| Days Payables Outstanding | 87.61 | 149.11 | 73.79 | 81.34 | 68.02 | 63.87 | 60.45 | 45.02 | 72.63 | 56.74 |
| Short-Term Debt | 0 | 0 | 3.75M | 0 | 0 | 1.44M | 0 | 1M | 2.82M | 1.5M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 13.26M | 29.77M | 27.84M | 25.78M | 3.91M | 12.81M | 14.61M | 25.45M | 46.92M | 31.59M |
| Current Ratio | 1.06x | 1.03x | 1.83x | 2.71x | 3.51x | 3.08x | 3.57x | 4.21x | 4.32x | 4.32x |
| Quick Ratio | 0.86x | 0.81x | 1.70x | 2.54x | 3.24x | 2.78x | 3.11x | 3.69x | 3.92x | 3.92x |
| Cash Conversion Cycle | 11.24 | 11.72 | 42.77 | 66.9 | 97.74 | 94.44 | 141.15 | 158.04 | 120.06 | 133.59 |
| Total Non-Current Liabilities | 1.65M | 1.64M | 65.45M | 51.45M | 53M | 53.37M | 50.32M | 25.21M | 21.84M | 21.19M |
| Long-Term Debt | 0 | 0 | 61.91M | 47.7M | 48.13M | 48.59M | 48.1M | 17.83M | 16.47M | 0 |
| Capital Lease Obligations | 0 | 0 | 2.92M | 2.96M | 3.92M | 2.44M | 0 | 4.71M | 3.25M | 3.25M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.65M | 1.64M | 621K | 795K | 951K | 2.33M | 2.22M | 2.68M | 2.13M | 35.82M |
| Total Liabilities | 47.46M | 73.19M | 132.77M | 110.61M | 95.35M | 96.92M | 96.33M | 70.81M | 86.11M | 65.74M |
| Total Debt | 286K | 229K | 69.74M | 51.83M | 53.29M | 52.47M | 48.1M | 24.84M | 22.53M | 1.5M |
| Net Debt | -27.19M | -44.89M | 674K | -43.98M | -33.79M | -13.48M | -33.9M | -79.57M | -143.59M | -158.27M |
| Debt / Equity | 0.00x | 0.00x | 2.03x | 0.57x | 0.58x | 0.70x | 0.34x | 0.13x | 0.09x | 0.09x |
| Debt / EBITDA | 0.01x | 0.08x | - | - | - | - | 1.19x | 0.38x | 0.29x | 0.03x |
| Net Debt / EBITDA | -0.52x | -15.00x | - | - | - | - | -0.84x | -1.23x | -1.82x | -1.82x |
| Interest Coverage | 538.08x | - | -4.40x | -5.59x | -1.42x | -2.94x | 5.75x | 58.96x | 38.16x | 25.32x |
| Total Equity | 73.8M▲ 0% | 49.66M▼ 32.7% | 34.4M▼ 30.7% | 91.42M▲ 165.8% | 92.58M▲ 1.3% | 74.51M▼ 19.5% | 142.72M▲ 91.6% | 193.11M▲ 35.3% | 256.55M▲ 32.9% | 242.94M▲ 0% |
| Equity Growth % | -44.51% | -32.71% | -30.73% | 165.77% | 1.27% | -19.52% | 91.55% | 35.31% | 32.85% | 113.58% |
| Book Value per Share | 0.64 | 0.47 | 0.32 | 0.84 | 0.84 | 0.66 | 0.98 | 1.30 | 1.71 | 1.64 |
| Total Shareholders' Equity | 73.8M | 49.66M | 34.4M | 91.42M | 92.58M | 74.51M | 142.72M | 193.11M | 256.55M | 242.94M |
| Common Stock | 113K | 113K | 113K | 113K | 113K | 114K | 146K | 147K | 148K | 149K |
| Retained Earnings | -46.58M | -76.56M | -102.14M | -151.42M | -161.71M | -191.91M | -133.68M | -91.26M | -42.68M | -53.54M |
| Treasury Stock | -44.38M | -38.64M | -10.81M | -7.45M | -4.02M | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -12.68M | -18.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MDXG Cash Flow Statement
MiMedx Group, Inc. (MDXG) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 62.94M | 35.8M | -39.41M | -30.26M | -1.98M | -17.89M | 26.77M | 66.2M | 74M | 74M |
| Operating CF Margin % | 19.6% | 9.97% | -13.17% | -12.19% | -0.82% | -6.68% | 8.33% | 18.97% | 17.68% | - |
| Operating CF Growth % | 143.69% | -43.13% | -210.1% | 23.21% | 93.45% | -802.77% | 249.64% | 147.24% | 11.79% | -16.11% |
| Net Income | 64.73M | -29.98M | -25.58M | -49.28M | -12.3M | -19.95M | 67.44M | 42M | 48.58M | 30.7M |
| Depreciation & Amortization | 5.76M | 6.92M | 7.58M | 6.86M | 5.18M | 4.05M | 3.43M | 6.04M | 14.88M | 16.5M |
| Stock-Based Compensation | 21.2M | 14.77M | 12.06M | 15.36M | 14.16M | 0 | 16.96M | 16.93M | 16.4M | 14.7M |
| Deferred Taxes | -26.67M | 25.54M | 1.58M | 0 | 0 | 0 | -37.8M | 12.47M | 8.71M | 4.18M |
| Other Non-Cash Items | -1.55M | -53K | -15M | 12.5M | 10.33M | 6.03M | -4.83M | -5.81M | 8.42M | -5.99M |
| Working Capital Changes | -523K | 18.6M | -20.05M | -15.69M | -19.35M | -8.01M | -18.42M | -5.43M | -22.98M | 3.48M |
| Change in Receivables | -479K | 16.45M | -10.94M | -3.1M | -10.62M | -5.94M | -12.24M | -2.55M | -26.39M | 9.02M |
| Change in Inventory | 2.75M | -6.52M | 6.88M | -1.26M | -1.41M | -1.79M | -7.84M | -2.36M | -1.53M | -2.16M |
| Change in Payables | -1.32M | 6.58M | -6.17M | 177K | -159K | 839K | 783K | -1.41M | 2.12M | 2.6M |
| Cash from Investing | -5.4M | -9.22M | 504K | -4.55M | -3.4M | -2.66M | -2.15M | -9.58M | -6.89M | -12.12M |
| Capital Expenditures | -5.4M | -10.03M | -2.22M | -4.23M | -3.22M | -2.68M | -2.15M | -1.72M | -3.12M | -192K |
| CapEx % of Revenue | 1.68% | 2.79% | 0.74% | 1.7% | 1.33% | 1% | 0.67% | 0.49% | 0.75% | - |
| Acquisitions | 0 | 30K | 0 | 0 | 0 | 24K | 0 | -7.86M | -3.76M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -271K | 808K | 2.72M | -327K | -177K | 0 | 0 | 0 | 0 | -11.93M |
| Cash from Financing | -60.39M | -8.93M | 62.86M | 61.56M | -3.35M | -580K | -8.57M | -34.2M | -5.41M | -5.12M |
| Debt Issued (Net) | -29K | -3K | 70.88M | -25.81M | -38K | -41K | -52K | -31.72M | -1M | -1.13M |
| Equity Issued (Net) | -72.34M | -12.49M | -1.47M | 97.67M | -4.75M | -539K | -8.52M | -2.64M | -3.12M | -2.56M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -72.34M | -12.49M | -1.47M | -2.33M | -4.75M | -1.19M | -9.52M | -2.64M | -3.12M | -2.56M |
| Other Financing | 11.99M | 3.56M | -6.54M | -10.29M | 1.44M | 0 | 0 | 159K | -1.29M | -1.43M |
| Net Change in Cash | -2.85M▲ 0% | 17.64M▲ 720.1% | 23.95M▲ 35.8% | 26.74M▲ 11.7% | -8.73M▼ 132.6% | -21.13M▼ 142.1% | 16.05M▲ 175.9% | 22.42M▲ 39.7% | 61.7M▲ 175.3% | 53.34M▲ 0% |
| Free Cash Flow | 57.54M▲ 0% | 25.77M▼ 55.2% | -41.63M▼ 261.6% | -34.49M▲ 17.1% | -5.2M▲ 84.9% | -19.41M▼ 273.2% | 24.79M▲ 227.7% | 64.52M▲ 160.3% | 72.97M▲ 13.1% | 66.07M▲ 0% |
| FCF Margin % | 17.92% | 7.18% | -13.91% | -13.89% | -2.15% | -7.25% | 7.71% | 18.49% | 17.43% | 16.97% |
| FCF Growth % | 207.43% | -55.22% | -261.56% | 17.15% | 84.92% | -273.21% | 227.73% | 160.27% | 13.11% | 11.54% |
| FCF per Share | 0.50 | 0.24 | -0.39 | -0.32 | -0.05 | -0.17 | 0.17 | 0.43 | 0.49 | 0.49 |
| FCF Conversion (FCF/Net Income) | 0.97x | -1.19x | 1.54x | 0.61x | 0.16x | 0.59x | 0.40x | 1.56x | 1.52x | 2.15x |
| Interest Paid | 0 | 0 | 0 | 7.46M | 4.33M | 0 | 0 | 2.7M | 0 | 728K |
| Taxes Paid | 0 | 0 | 0 | 208K | 169K | 0 | 0 | 3.25M | 0 | 4.06M |
MDXG Key Ratios
MiMedx Group, Inc. (MDXG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 62.6% | -48.57% | -60.87% | -78.34% | -13.37% | -36.15% | 62.09% | 25.26% | 21.61% | 12.86% |
| Return on Invested Capital (ROIC) | 47.74% | -11.46% | -79.67% | -82.53% | -9.96% | -18.44% | 32.78% | 39.71% | 42.31% | 42.31% |
| Gross Margin | 89.03% | 89.87% | 85.6% | 84.16% | 83.63% | 81.96% | 83.01% | 82.78% | 82.56% | 81.04% |
| Net Margin | 20.16% | -8.35% | -8.55% | -19.85% | -5.08% | -11.27% | 20.98% | 12.16% | 11.6% | 7.88% |
| Debt / Equity | 0.00x | 0.00x | 2.03x | 0.57x | 0.58x | 0.70x | 0.34x | 0.13x | 0.09x | 0.09x |
| Interest Coverage | 538.08x | - | -4.40x | -5.59x | -1.42x | -2.94x | 5.75x | 58.96x | 38.16x | 25.32x |
| FCF Conversion | 0.97x | -1.19x | 1.54x | 0.61x | 0.16x | 0.59x | 0.40x | 1.56x | 1.52x | 2.15x |
| Revenue Growth | 31.07% | 11.82% | -16.67% | -17.05% | -2.5% | 10.67% | 20.03% | 8.52% | 19.99% | 10.51% |
MDXG SEC Filings & Documents
MiMedx Group, Inc. (MDXG) SEC filings — annual & quarterly reports (10-K, 10-Q)
MDXG Frequently Asked Questions
MiMedx Group, Inc. (MDXG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MiMedx Group, Inc. (MDXG) reported $389.4M in revenue for fiscal year 2025.
MiMedx Group, Inc. (MDXG) grew revenue by 20.0% over the past year. This is strong growth.
Yes, MiMedx Group, Inc. (MDXG) is profitable, generating $30.7M in net income for fiscal year 2025 (11.6% net margin).
Dividend & Returns
MiMedx Group, Inc. (MDXG) has a return on equity (ROE) of 21.6%. This is excellent, indicating efficient use of shareholder capital.
MiMedx Group, Inc. (MDXG) generated $66.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More MDXG
MiMedx Group, Inc. (MDXG) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates